ISSN:
1569-8041
Keywords:
JM216
;
lung cancer
;
non-small cell
;
oral chemotherapy
;
platinum
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background: JM216 is a new oral platinum complex with dose-limitingtoxicity myelosuppresssion, now undergoing phase II evaluation. Patients and methods: JM216 was evaluated as first line therapy innon-small-cell lung cancer. 17 patients received 120 mg/m2/dayfor five days repeated every three weeks. Results: Toxicity was manageable, the commonest side-effects being nausea,vomiting, diarrhoea, constipation and asthenia. Myelososuppression wasgenerally grade 〈2 and there were no cases of neutropenic sepsis orbleeding. Thirteen patients were fully evaluable for response. No sustainedobjective responses were reported. One patient was reported as stable diseasehad a partial response after three courses but was progressing again afterfour. An additional five patients had stable disease (46.2%). Conclusions: Although some patients may have had useful palliation, JM216did not appear to have significant antitumour activity in non-small-cell lungcancer.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008245709924
Permalink
